Silencing of BAF53a in RMS cells inhibited cell proliferation and anchorage-independent growth in vitro, inhibited ERMS and ARMS tumor growth, and induced myogenic differentiation in vivo, therefore, leading to the conclusion that failure to downregulate the BAF53a subunit may contribute to RMS pathogenesis [29]. Here, ACTL6A is linked to neoplasm.